Presentation ACC 2017 EINSTEIN CHOICE: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism Presenter: Jeff Weitz March 20, 2017 REGISTER for free or LOG IN to view this content Clinical Cardiology Clinical Pharma Prevention Presentation ACC 2017 Up Next Presentation ACC 2017 Results of the CARAT Study: Effect of Serial Infusions of CER-001, a Pre-Beta High-Density Lipoprotein Mimetic on Coronary Atherosclerosis Presenter: Stephen J Nicholls March 20, 2017 More slides + Presentation ACC 2017 iFR vs FFR-guided Coronary Intervention – iFR-SWEDEHEART Presenter: Matthias Götberg March 20, 2017 Presentation ACC 2017 Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Presenter: Stephen G. Ellis March 19, 2017 We Recommend
Presentation ACC 2017 Results of the CARAT Study: Effect of Serial Infusions of CER-001, a Pre-Beta High-Density Lipoprotein Mimetic on Coronary Atherosclerosis Presenter: Stephen J Nicholls March 20, 2017
Presentation ACC 2017 iFR vs FFR-guided Coronary Intervention – iFR-SWEDEHEART Presenter: Matthias Götberg March 20, 2017
Presentation ACC 2017 Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Presenter: Stephen G. Ellis March 19, 2017